Statement on 340B Orphan Drug Court Decision
EXECUTIVE VICE PRESIDENT
AMERICAN HOSPITAL ASSOCIATION
October 15, 2015
We are very disappointed that the U.S. District Court for the District of Columbia late last night ruled against the Department of Health and Human Services in a lawsuit brought by the Pharmaceutical Research and Manufacturers of America (PhRMA).
This decision comes at a steep cost for the vulnerable patients cared for by rural and cancer hospitals. The ruling excludes all drugs with an “orphan” designation from the 340B Drug Pricing Program for rural and cancer hospitals. Denying these hospitals the ability to utilize 340B discounts for these drugs will reduce access to critical services and treatments for some of the most vulnerable patients in society. Sadly, the biggest beneficiary of this ruling is the pharmaceutical industry – it does nothing to help either patients or taxpayers.
About the AHA
The AHA is a not-for-profit association of health care provider organizations and individuals that are committed to the health improvement of their communities. The AHA is the national advocate for its members, which include nearly 5,000 hospitals, health care systems, networks, other providers of care and 43,000 individual members. Founded in 1898, the AHA provides education for health care leaders and is a source of information on health care issues and trends. For more information, visit the AHA website at www.aha.org.
- AHA's HRET, others receive contracts to continue HAC, readmissions progress
- CMS to resume hospital appeals settlements
- President signs government, Zika funding bill into law
- Senators introduce bill to bolster rural health care
- AHA expresses support for Closing Loopholes for Orphan Drugs Act